Commonwealth Biotechnologies Inc.

Bill Guo MSc, MBA . Bill Guo is our acting Chief Executive Officer and Chairman of our Board of Directors. Mr. Guo is the Chairman and founder of VenturePharm Group, a leading full service pharmaceutical company in Asia, and led its flagship VenturePharm Laboratories ( HK.8225 ) to become the first clinical research organization listed on the Hong Kong Stock Exchange. He has over 10 years global pharmaceutical industry experience from researcher to senior executive in North America at Johnson & Johnson, Novapharm and VenturePharm Canada. He has over 9 years of experience as an entrepreneur in China. Mr. Guo was a Ph.D. candidate in the Department of Pharmaceutics and was awarded an MSc degree in industrial pharmacy from the University of Toronto, Toronto, Canada, an MBA program certificate from Herriot Watt University, Toronto, Canada, and an Executive education certificate from Judge Business School, University of Cambridge, UK. Fortune magazine recognized him as one of the top emerging entrepreneurs in China. He was also recipient of various rewards: 2005 National Hero awarded by the State Council of China; one of the ten best management elites in China in 2004; one of the ten most influential individuals in business in China, 2005; distinguished entrepreneur awarded from overseas by government of China, 2005; sole winner of Youth Chinese Entrepreneur Award organized by Asia Business Week in 2003 and 2005 Entrepreneurs and innovation by BCC (British Chamber of Commerce). Mr. Guo s term as a director runs through 2011, or until his successor is appointed.

Richard J. Freer, Ph.D . Since co-founding CBI in 1992, Dr. Freer has served as a director of CBI and, until 2008, as the Chairman of the Board of CBI. He assumed the role of Chief Operating Officer in 2002. From 1975 until 1997, Dr. Freer was employed in the Department of Pharmacology and Toxicology at Virginia Commonwealth University ( VCU ), first as an Associate Professor and then a full Professor. In addition, from 1988 through 1995, Dr. Freer was first Director and then Chair of the Biomedical Engineering Program. From 1996 through 1997, Dr. Freer served as Professor in VCU s Department of Biochemistry and Molecular Biophysics. Dr. Freer received a bachelor s degree in Biology from Marist College and a doctorate degree in Pharmacology from Columbia University. Dr. Freer s term as a director runs through 2009, or until his successor is appointed.

Since founding Commonwealth Biotechnologies, Inc., in 1992 with three other partners, Mr. Reynolds has served as Vice President, Senior Vice President and Executive Vice President as well as a Director of the Company. Unitl recently, Mr. Reynolds was Secretary of the Board of Directors.. Mr. Reynolds is responsible for oversight of all DNA related technologies and services including management oversight of the Fairfax Identity Laboratory division. From 1987 until 1997, Mr. Reynolds served as Manager of the Nucleic Acids Core Laboratory at The Massey Cancer Center in the Department of Microbiology Biology and Immunology at Virginia Commonwealth University. From 1984 through 1986, Reynolds served as a research assistant in Genetics at Carnegie Mellon University. Mr. Reynolds is a co-inventor of several US patents, and co-author of more than 35 peer reviewed journal articles and book chapters, in the research area of molecular genetics.

Dr. McAfee is Cardiome’s Chief Scientific Officer. He joined Cardiome in October 2004 as Vice President of New Product Development. He has been a scientist and manager in academia and industry for more than 40 years. As Founder, CEO, and CTO of Aderis Pharmaceuticals, Inc. (formerly Discovery Therapeutics, Inc.), Dr. McAfee led the introduction of a number of clinical candidates including a therapeutic patch for Parkinson’s disease now marketed, and adenosine receptor based cardiovascular therapeutics and diagnostics still in development.

James H. Brennan was promoted to Vice President, Financial Operations in December 2005 and continues to serve as an officer of the Company. From 1997 until 2005, Mr. Brennan was previously Controller for the Company. During his tenure, Mr. Brennan is responsible finance and accounting, treasury, human resources and investor relations. Prior to joining the Company, (1988 until 1997), Mr. Brennan's other work experience included, corporate controller for Star Tobacco and Pharmaceuticals, Delta Airport Consultants, Herald Pharmaceuticals and, Christian Children's Fund. From 1980 until 1988, Mr. Brennan worked for the Coca Cola Bottling Company as Plant Controller, Systems Analyst and Corporate Accounting Manager. Mr. Brennan holds a BA from Mount Saint Mary's College and an MBA from Averett University.

Dr. Kelly joined Commonwealth Biotechnologies, Inc. in December 2004 with the acquisition by CBI of Fairfax Identity Laboratories (FIL), where he is the Director of the DNA Reference Laboratory. Dr. Kelly joined FIL in 1996 where he has been both head of the Paternity lab and the CODIS lab, with the exception of a one-year leave to participate in the identification of remains of the victims of the World Trade Center attack. Prior to joining FIL Dr. Kelly was a member of the faculty of the Biology Department at the University of North Carolina at Greensboro for seven years and Director of Parentage Analysis at Genetic Design, Inc., the largest paternity testing company at the time. He received his Bachelor of Science degree from Carnegie Mellon University in Pittsburgh, PA, and his Ph.D. from Purdue University in West Lafayette, IN. His postdoctoral research and teaching experience included time at the Anatomy Department of Case Western Reserve University in Cleveland, OH, and the Departments of Anatomy and Physiology at the Duke University Medical Center. Dr. Kelly is a member of numerous professional societies and has both published in books and peer reviewed journals as well as given numerous presentations before both scientific and civic groups.

Ms. Ellett is the Manager of CBI's Quality Assurance Unit. Ellett deals directly with CBI clients who require QA oversight and whose projects must meet GLP reporting requirements. Ellett wrote the Laboratory Quality Assurance Manual for CBI and is involved in maintaining cGLP compliance for the company. Ms. Ellett has 25 years experience in the clinical laboratory and has a bachelor's degree with certification in medical technology.

Teller is considered expert in virtually all aspects of IT and holds professional certifications attesting to his expertise in Mac, Apple, Linux, CompTia, and MCP. While employed at the University of Richmond computing center, Teller became versed in different operating systems, including Mac OS Classic-Mac OS X, Linux, RedHat, Solaris 2.6-8, Windows (including all server systems, DOS, and IBM OS2. At CBI, Teller is responsible for all aspects of computer maintenance and troubleshooting, with special emphasis on CBI's server, telecommunications, and security networks. Teller provides all end-user support, education, and guidance on computer systems and integration with laboratory instrumentation.

Ms. Johnson is our Forensic Manager and as such directs the operation of the Forensic service lab. She has been involved in thousands of cases during her nine year career. Before working at CBI-FIL she spent 3 years at the Armed Forces DNA Identification Laboratory where she specialized in mtDNA analysis to identify the remains of those who have perished during military mishaps. Her DNA analysis experience also includes 6 years of experience performing both mtDNA and STR casework at The Bode Technology Group, Inc. She has performed all aspects of forensic analysis to include consultation, evaluation, screening, extraction, amplification, analysis, interpretation, reporting, statistics, case review and expert witness testimony. She has analyzed various types of biological specimens to include blood, skeletal material, tissue, hair, teeth, human nails, saliva, urine, and semen as well as various substrates containing biological material. She has performed mtDNA and/or STR analysis for the following: The Tomb of the Unknown Soldier, The National Center for Missing and Exploited Children (NCMEC), The International Commission on Missing Persons (ICMP)-Bosnia and Croatia, The Innocence Project-(Charles Fain, Christopher Ochoa and Richard Danziger), The World Trade Center (WTC), Alaska Air Flight 261, American Airlines Flight 587, as well as numerous sexual assault and forensic cases.

At CBI, Ms. Crabtree is the first point of contact for most of our customers. In her capacity as Lab Manager, Tammie prepares quotations, answers customer queries, accepts incoming orders, distributes samples for analysis and does sample follow-up. She is responsible for operational up-keep of lab equipment, management of client records and CBI's peptide and chemical inventory databases. She is considered expert in most areas of automated peptide synthesis and directs CBI's preparative HPLC lab used for peptide and protein purification. Tammie has been instrumental in helping to establish CBI's unique extraction protocol of toxins from environmental samples. Formerly with Environment 1, Inc. in Greenville, NC, Tammie came to CBI in 1998. She received the BS degree in Biology from East Carolina University and is the recipient of several academic awards.

Dr. Miller is part of the Biological Chemistries group at CBI and is considered expert in all aspects of protein purification and characterization, including all methods of chromatography and biophysical analyses. Dr. Miller has been instrumental in establishing CBI's proteomics program in 2D PAGE analyses. Dr. Miller received her Ph.D. in biochemistry from the Medical College of Georgia and is the author of peer reviewed research papers. Dr. Miller is also the recipient of several awards, including a prestigious Sigma Xi award for academic excellence.

Dr. Horejsh earned his Ph.D from the competitive CMB program at the University of Wisconsin where he was trained in retrovirology. He continued his postdoctoral studies at the Institute of Human Virology in Baltimore, MD. He was recruited to CBI in May, 2006, from the Italian National Institute for Infectious Diseases, Rome, Italy were he was a Scientist and Consultant working with SARS, orthopoxviruses, flaviviruses, and avian influenza. Dr. Horejsh was nominated for a "Lazio Innovation Award" for developing a bead-based DNA detection method. He led efforts to modify existing technologies for rapid differential diagnosis of viral infection, resulting in two patents. Dr. Horejsh has published 17 articles in international journals and was an invited speaker at the US-Italy bilateral meeting on emerging and bio-threat pathogens. At CBI, Dr. Horejsh is involved in all aspects of pathogen growth, isolation, testing, and analysis.

Mr. Meyers supervises CBI's high throughput DNA Services Lab. Mr. Meyers has been with CBI almost from its inception where he was a pivotal player in the initiation of many of the DNA services offered at CBI. He is considered expert in all aspects of DNA structure determination, and helped pioneer new processes of high throughput DNA sequence analysis and detection. Meyers is the co-inventor of AccuTrac , a reagent formulated at CBI to facilitate lane tracking on automated DNA sequence gels. Meyers has extensive experience in DNA sequence analysis, genotyping, and SNP detection. After five years at CBI he moved to North Carolina where he worked as both a Group Leader for genotyping and Project Manager at Icoria, Inc. (formerly Paradigm Genetics, Inc.), Research Triangle Park, NC, and a Product Manager for SNP analysis and genomic instruments, at MWG Biotech, Inc, High Point, NC. Mr. Meyers rejoined CBI in 2004. Meyers obtained his B.S. degree from Virginia Tech in Microbiology and his M.S. Degree from Virginia Commonwealth University, in Molecular Biology and Genetics. In addition to his patents, Meyers is a co-author on numerous peer reviewed research papers and is the recipient of academic and industry awards and honors.

Jay Donovan has had more then 25 years experience in Sales and Marketing and more then 18 years involved in case production, sales, marketing and product development in the genetic testing industry. Mr. Donovan came to Fairfax Identity Laboratories (FIL) to organize and implement an in-house sales program. He was also responsible for the creation of FIL's Value Added Reseller programs as well as the conception, design and implementation of FIL's Home Identity Test series (HIT) and FIL's popular downloadable kit systems (QuickHIT). Recently, he has been active in the development of FIL's Assure and eHIT product lines. Mr. Donovan graduated from Radford University and holds a Bachelor of Science degree.

Mr. Buettner has over 22 years experience in all aspects of drug development including small molecule, peptide (mimetic) synthesis, protein structure analysis, in vitro biochemistry assays, animal studies, and formal project development and management. Mr. Buettner came to CBI from the Bayer Corporation, Biological Products Division, in North Carolina where he held positions in discovery research, assay development and Project Management. Chief among his talents is analytical chemistry, including expertise in mass spec analysis and in particular in ES/MS and associated methods as performed on a Q TOF instrument. Mr. Buettner interacts with clients and is responsible for sample analysis within the bioorganic laboratory, including analysis of select agent toxins. He received his MS degree in Microbiology from the University of Wyoming, Laramie, WY, and is the recipient of academic and industry awards. He is co-author of 8 issued patents and 19 refereed journal references.

Ms. McVoy joined the Company in April, 1994 and has since been promoted to Senior Scientist. Ms. McVoy is considered an expert in all aspects of immunochemistry and immunoassay and has taken charge of the Company's efforts in assay development. Ms. McVoy received her Bachelor's degree in Biology from the College of William and Mary, and her Master of Science degree in Human Genetics from Virginia Commonwealth University, the Medical College of Virginia. Ms. McVoy is the recipient of many awards for scientific excellence and helped develop assay methods for biotinidase deficiency, including an assay that is currently used in neonatal screening programs throughout the world. Ms. McVoy is the co-author of numerous peer reviewed journal articles in the general areas of her research expertise, human biochemical genetics.

Dr. Carter came to CBI in 2008 to head up CBI's organic chemistry efforts. Carter leads many of CBI's bio-defense related programs. She has extensive experience in the design, synthesis and characterization of small molecules with defined pharmacological and physiological properties. Dr. Carter is considered expert in methods development and in the application of NMR, FTIR, GC/MS RP HPLC and mass spectrometry to modern synthesis approaches. She received the Ph.D. in organic chemistry from the University of Virginia, and is the author of numerous peer reviewed papers on synthesis and use of receptor agonists.

Dr."Swamy" joined the Company in January, 1997, as Senior Scientist. Prior to joining the Company, Swamy was on the faculty of Virginia Commonwealth University, first in the Department of Pharmacology & Toxicology (1977-1992) and then in the Department of Biomedical Engineering (1992-1997). Swamy is an integral member of the peptide synthesis group, and is expert in all phases of solid-phase and solution-phase chemical synthesis of peptides and peptide analogs. Swamy received the Bachelor's and Masters degrees in Chemistry from Madras University, Madras, India, and the Doctoral degree in Organic Chemistry from the same institution. He is the co-author of more than 30 peer reviewed journal articles and book chapters.

Dr. Helber brings 17 years of combined biotechnology and academic experience to CBI. Prior to CBI, Dr. Helber was an Assistant Professor in the Department of Pharmacology/Toxicology at Virginia Commonwealth University, where she supervised the research of technicians, graduate students, and post-doctoral fellows in numerous projects in the areas of molecular and cell biology and immunology. At CBI, Dr. Helber oversees the support work of a wide variety of clinical trials, including vaccine development and the molecular diagnostics of cancer. Dr. Helber received her Bachelor of Science in Biology from Bucknell University in Lewisburg, PA in 1986. She received her PhD in Microbiology/Immunology from the Medical College of Virginia campus of Virginia Commonwealth University in 1993. Dr, Helber is author on numerous peer-reviewed publications in the area of molecular biology of erythropoeisis.

Dr. Wolz joined the Company in August, 1996, as Senior Research Scientist and has been promoted to Group Leader. Wolz heads the Company's biochemistry research services. Until 1996, Wolz was Assistant Professor at Indiana University of Pennsylvania, and was previously an Assistant Professor in the Department of Biochemistry and Molecular Biology at the Penn State University College of Medicine, Hershey, PA. Dr. Wolz received a Bachelor's degree in Chemistry from Colorado State University, and the Doctoral degree from Northwestern University, in Biochemistry. Wolz is the co-author of more than 15 peer reviewed journal articles and book chapters in the general areas of his research expertise, protein structure and function. Wolz is credited with co-discovery of the zinc binding motif common to all zinc-metallo proteinases. Wolz is the Principal Investigator on Phase I and Phase II Small Business Innovative Research Awards issued to the Company from the NIH and USDA, respectively.